To: Jenna who wrote (91623 ) 4/4/2000 9:55:00 PM From: Jenna Respond to of 120523
ADRX..ELN and also generic drug companies. ADRX double bottom breakout, a split, resistance pierced at 55. Stochastics are not showing an overbought reading. ADRX is looking like more upside and not everyone and their grandmother are buying it for safety. AKRN did very well until it corrected, its earning nice money and it was upgraded to strong buy after earnings came out. BRL looks fine also probably my favorite. MYL is also doing well. Kendal mentioned ALO a while back and that's nice. Generic drugs work well and in some cases even have less side effects than the 'real thing' They should but "hazard: dangerous for your financial health" on all drug stocks however. I like to hold them sparingly, churn them quite a bit and only for position trades. ELN has a beautiful chart. This is how the entire nasdaq should look or at least any stock you buy longer term. ELN looks better than most of the techs or drug stocks. I've had BMY it was okay but not great. Its broken out but I wouldn't park all my money in American drug stocks. I'd rather park money in HSY, NGH or NH or KO. There are no surprises there. Chocolate will always be wanted, especially if the market is down and people get depressed. Nabisco will always have cookies and wash it down with coke. Drug stocks are different. I like the generic drug companies best and not the American ones. Just a preference. I've had ELN and TEVA for years but TEVA was a sell and I'm waiting to rebuy. BMY looks like a place to put your money while in transit between the companies of your choice. They went up modestly but any change in the drug sector and they can turn out just like the financials. More on MYL: UPDATE 1-U.S. study compares high blood pressure drugs (Updates with details, paras 2,3,6) CHICAGO, April 4 (Reuters) - Thinning the blood rather than trying to make arteries more open and relaxed may be the better and safer approach for treating some people with high blood pressure, according to a study released on Tuesday. In a finding released ahead of its scheduled publication date following disclosure at a medical meeting in California last month, researchers said they stopped using an artery-influencing drug, an alpha-blocker called doxazosin, in a large test. Doxazosin users had 25 percent more cardiovascular events and were twice as likely to be hospitalized for congestive heart failure as users of a diuretic called chlorthalidone. The drugs were similarly effective in preventing heart attacks and in reducing the risk of death from all causes. ``We showed that study participants who took chlorthalidone cut the risk of heart failure in half, compared to those who took doxazosin,' said Bary Davis of the University of Texas-houston School of Public Health.Pfizer Inc. (NYSE:PFE - news) sells doxazosin under the Cardura brand name. Mylan Laboratories Inc. (NYSE:MYL - news) sells chlorthalidone as Hygroton.